VACTERL/VATER Association Benjamin D Solomon
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
VATER/VACTERL Association in Palestinian Children: a Case Report
www.symbiosisonline.org Symbiosis www.symbiosisonlinepublishing.com Research Article International Journal of Pediatrics & Child Care Open Access VATER/VACTERL Association in Palestinian Children: A Case Report Basal A Ahmed1, Elessi Khamis2* 1Specialist and Head of Pediatrics, Shaheed Mohammed Al - Durra Hospital 2Assistant Professor, Faculty of medicine, Islamic university- Gaza Received:December 13, 2017; Accepted: February 3, 2018; Published: February 6, 2018 *Corresponding author: Elessi Khamis, MD Pediatrics, Assistant Professor, Faculty of medicine, Islamic university- Gaza, E-mail: khamis_essi@yahoo. com have reported a prevalence among infants of one in 10 000 to one Abstract of at least three of the following congenital malformations: vertebral however,in 40 000 live-bornchromosomal infants abnormalities (approximately have <1-9/100,000 also been described infants) VACTERL/VATER association is typically defined by the presence [2]. Most of the cases of VACTERL association occur sporadically; defects, anal atresia, cardiac defects, tracheo-esophageal fistula, stress and usage of oral contraceptives at the initial stages of by evidence linking all of the human disease genes for the VATER/ in a few cases [3]. Maternal diabetes, teratogenic drugs, physical renal anomalies, and limb abnormalities. This finding is supported pregnancy have been suggested as possible causes [4]. VACTERL is believed to result from an early embryonic insult, more VACTERL association identified to date, namely, FGF8, FOXF1, HOXD13, LPP, TRAP1, and ZIC3, with renal malformations. VATER association was first described in 1972 by Quan and Smith. We present here a specifically of blastogenic origin occurring during the first 4 75 days male boy with cardiac (VSD, PDA), esophageal atresia, anal weeks of embryogenesis, so the expected effects are primary, abnormalities (sacral dimple), and genitourinary (hypospadias and polytopic,This early developmental embryonic field event defects can [5]lead (Figure to different 1). -
New Microdeletion and Microduplication Syndromes: a Comprehensive Review
Genetics and Molecular Biology, 37, 1 (suppl), 210-219 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article New microdeletion and microduplication syndromes: A comprehensive review Julián Nevado1,2*, Rafaella Mergener3*, María Palomares-Bralo1,2, Karen Regina Souza3, Elena Vallespín1,2, Rocío Mena1,2, Víctor Martínez-Glez1,2, María Ángeles Mori1,2, Fernando Santos1,4, Sixto García-Miñaur1,4, Fé García-Santiago1,5, Elena Mansilla1,5, Luis Fernández1,6, María Luisa de Torres1,5, Mariluce Riegel3,7$ and Pablo Lapunzina1,4,8$ 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Section of Functional and Structural Genomics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre,RS, Brazil. 4Section of Clinical Genetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 5Section of Cytogenetics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 6Section of Preanalytics, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 7Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre ,RS, Brazil. 8Section of Molecular Endocrinology, Overgrowth Disordes Laboratory, Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. Abstract Several new microdeletion and microduplication syndromes are emerging as disorders that have been proven to cause multisystem pathologies frequently associated with intellectual disability (ID), multiple congenital anomalies (MCA), autistic spectrum disorders (ASD) and other phenotypic findings. In this paper, we review the “new” and emergent microdeletion and microduplication syndromes that have been described and recognized in recent years with the aim of summarizing their main characteristics and chromosomal regions involved. -
Holt-Oram Syndrome: a Clinical Genetic Study J Med Genet: First Published As 10.1136/Jmg.33.4.300 on 1 April 1996
300_0fMed Genet 1996;33:300-307 Holt-Oram syndrome: a clinical genetic study J Med Genet: first published as 10.1136/jmg.33.4.300 on 1 April 1996. Downloaded from R A Newbury-Ecob, R Leanage, J A Raebum, I D Young Abstract to clarify the spectrum of abnormalities and to A clinical and genetic study of the Holt- delineate the HOS phenotype led us to review Oram syndrome (HOS) has been carried the clinical features in our patients, and dis- out in the United Kingdom involving 55 tinguish the clinical features most helpful for cases designated Holt-Oram syndrome, counselling purposes. together with their parents and sibs. Data This study was carried out in conjunction from the clinical assessment of both fa- with a genetic linkage study which has shown milial and isolated cases were used to de- genetic heterogeneity in the Holt-Oram syn- fine the HOS phenotype and to outline drome, with one gene (HOS1) being localised the spectrum of abnormalities, especially to chromosome 12 in five out ofseven families.7 factors affecting severity. Skeletal defects No phenotypic differences could be detected affected the upper limbs exclusively and between the linked and unlinked families. were bilateral and asymmetrical. They ranged from minor signs such as clino- dactyly, limited supination, and sloping Patients and methods shoulders to severe reduction deformities The study was carried out between March 1991 of the upper arm (4.5%). The radial ray and September 1993. Cases were ascertained was predominantly affected and the left by contacting clinical geneticists and paediatric side was more severely affected than the cardiologists and through the support group right. -
Megalencephaly and Macrocephaly
277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ► -
Level Estimates of Maternal Smoking and Nicotine Replacement Therapy During Pregnancy
Using primary care data to assess population- level estimates of maternal smoking and nicotine replacement therapy during pregnancy Nafeesa Nooruddin Dhalwani BSc MSc Thesis submitted to the University of Nottingham for the degree of Doctor of Philosophy November 2014 ABSTRACT Background: Smoking in pregnancy is the most significant preventable cause of poor health outcomes for women and their babies and, therefore, is a major public health concern. In the UK there is a wide range of interventions and support for pregnant women who want to quit. One of these is nicotine replacement therapy (NRT) which has been widely available for retail purchase and prescribing to pregnant women since 2005. However, measures of NRT prescribing in pregnant women are scarce. These measures are vital to assess its usefulness in smoking cessation during pregnancy at a population level. Furthermore, evidence of NRT safety in pregnancy for the mother and child’s health so far is nebulous, with existing studies being small or using retrospectively reported exposures. Aims and Objectives: The main aim of this work was to assess population- level estimates of maternal smoking and NRT prescribing in pregnancy and the safety of NRT for both the mother and the child in the UK. Currently, the only population-level data on UK maternal smoking are from repeated cross-sectional surveys or routinely collected maternity data during pregnancy or at delivery. These obtain information at one point in time, and there are no population-level data on NRT use available. As a novel approach, therefore, this thesis used the routinely collected primary care data that are currently available for approximately 6% of the UK population and provide longitudinal/prospectively recorded information throughout pregnancy. -
Prenatal Diagnosis of Frequently Seen Fetal Syndromes (AZ)
Prenatal diagnosis of frequently seen fetal syndromes (A-Z) Ibrahim Bildirici,MD Professor of OBGYN ACIBADEM University SOM Attending Perinatologist ACIBADEM MASLAK Hospital Amniotic band sequence: Amniotic band sequence refers to a highly variable spectrum of congenital anomalies that occur in association with amniotic bands The estimated incidence of ABS ranges from 1:1200 to 1:15,000 in live births, and 1:70 in stillbirths Anomalies include: Craniofacial abnormalities — eg, encephalocele, exencephaly, clefts, which are often in unusual locations; anencephaly. Body wall defects (especially if not in the midline), abdominal or thoracic contents may herniate through a body wall defect and into the amniotic cavity. Limb defects — constriction rings, amputation, syndactyly, clubfoot, hand deformities, lymphedema distal to a constriction ring. Visceral defects — eg, lung hypoplasia. Other — Autotransplanted tissue on skin tags, spinal defects, scoliosis, ambiguous genitalia, short umbilical cord due to restricted motion of the fetus Arthrogryposis •Multiple congenital joint contractures/ankyloses involving two or more body areas •Pena Shokeir phenotype micrognathia, multiple contractures, camptodactyly (persistent finger flexion), polyhydramnios *many are AR *Lethal due to pulmonary hypoplasia • Distal arthrogryposis Subset of non-progressive contractures w/o associated primary neurologic or muscle disease Beckwith Wiedemannn Syndrome Macrosomia Hemihyperplasia Macroglossia Ventral wall defects Predisposition to embryonal tumors Neonatal hypoglycemia Variable developmental delay 85% sporadic with normal karyotype 10-15% autosomal dominant inheritance 10-20% with paternal uniparental disomy (Both copies of 11p15 derived from father) ***Imprinting related disorder 1/13 000. Binder Phenotype a flat profile and depressed nasal bridge. Short nose, short columella, flat naso-labial angle and perialar flattening Isolated Binder Phenotype transmission would be autosomal dominant Binder Phenotype can also be an important sign of chondrodysplasia punctata (CDDP) 1. -
TARGETED GENE PANELS and REFERENCE SEQUENCE (Refseq) TRANSCRIPTS by PHENOTYPE
ROYAL DEVON & EXETER NHS FOUNDATION TRUST Department of Molecular Genetics TARGETED GENE PANELS AND REFERENCE SEQUENCE (RefSeq) TRANSCRIPTS BY PHENOTYPE Table of Contents (Click to select) Alagille Syndrome 2 Chondrodysplasia punctata 2 Combined Pituitary Hormone Deficiency 2 Congenital Generalised Lipodystrophy 2 Congenital Hypothyroidism 2 Early-onset Diabetes and Autoimmunity 3 Endocrine Neoplasia Syndromes 3 Familial Glucocorticoid Deficiency 3 Familial Hyperparathyroidism 3 Familial Hypocalciuric Hypercalcaemia 3 Familial Hyperparathyroidism/hypercalcaemia 4 Familial Hypoparathyroidism 4 Familial Partial Lipodystrophy 4 Familial Porencephaly and HANAC syndrome 4 Familial Tumoral Calcinosis 4 Feingold syndrome 4 Gastrointestinal atresia 5 Generalised Arterial Calcification in Infancy 5 Holoprosencephaly 5 Hyperinsulinism 5 Hypophosphatemic Rickets 6 Isolated Growth Hormone Deficiency 6 Kabuki syndrome 6 Kallmann syndrome 6 Mandibulofacial Dysostosis with Microcephaly 6 Moebius syndrome 6 Monogenic Diabetes of the Young (MODY) 7 Multiple Exostosis 7 Neonatal Diabetes 8 Phaeochromocytoma/Paraganglioma 9 Pontocerebellar Hypoplasia 9 Primary pigmented nodular adrenocortical disease 9 Pseudohypoaldosteronism 9 Spondylocostal Dysostosis 9 Visceral heterotaxy 10 Page 1 of 10 ROYAL DEVON & EXETER NHS FOUNDATION TRUST Department of Molecular Genetics Alagille Syndrome Transcript(s) JAG1 NM_000214 NOTCH2 NM_024408 Chondrodysplasia punctata Transcript(s) AGPS NM_003659 ARSE NM_000047 EBP NM_006579 GNPAT NM_014236 PEX7 NM_000288 Combined Pituitary -
WES Gene Package Multiple Congenital Anomalie.Xlsx
Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar, -
(12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep. -
Case Report Upper Limb Meromelia with Oligodactyly and Brachymesophalangy of the Foot: an Unusual Association
Hindawi Case Reports in Radiology Volume 2019, Article ID 3419383, 5 pages https://doi.org/10.1155/2019/3419383 Case Report Upper Limb Meromelia with Oligodactyly and Brachymesophalangy of the Foot: An Unusual Association Meltem Özdemir , Rasime Pelin Kavak , and Önder Eraslan University of Health Sciences, Dıs¸kapı Yıldırım Beyazıt Training and Research Hospital, Department of Radiology, Ankara, Turkey Correspondence should be addressed to Meltem Ozdemir;¨ [email protected] Received 1 May 2019; Accepted 7 June 2019; Published 24 June 2019 Academic Editor: Ravi Bhargava Copyright © 2019 Meltem Ozdemir¨ et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Meromelia is a rare skeletal abnormality characterized by the partial absence of at least one limb. Several mechanisms have been postulated to explain the etiopathogenesis of the disorder. Most of the cases of meromelia are reported to be sporadic. It can occur either in isolation or with other congenital malformations. VACTERL association, gastroschisis, atrial septal defect, proximal femoral focal defciency, and fbular hemimelia are the congenital abnormalities reported to be in association with meromelia. However, no other congenital abnormalities in association with meromelia have been recorded to date. We herein present an unusual case of bilateral upper limb meromelia accompanied by unilateral oligodactyly and brachymesophalangy of the foot. 1. Introduction herein present an unusual case of meromelia accompanied by congenital deformity of the foot. Amelia refers to the complete absence of at least one limb, and meromelia is characterized by the partial absence of at least one limb. -
MED12 Mutations Link Intellectual Disability Syndromes with Dysregulated GLI3-Dependent Sonic Hedgehog Signaling
MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling Haiying Zhoua, Jason M. Spaethb, Nam Hee Kimb, Xuan Xub, Michael J. Friezc, Charles E. Schwartzc, and Thomas G. Boyerb,1 aDepartment of Molecular and Cell Biology, Howard Hughes Medical Institute, University of California, Berkeley, CA 94270; bDepartment of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229; and cGreenwood Genetic Center, Greenwood, SC 29646 Edited by Robert G. Roeder, The Rockefeller University, New York, NY, and approved September 13, 2012 (received for review December 20, 2011) Recurrent missense mutations in the RNA polymerase II Mediator divergent “tail” and “kinase” modules through which most activa- subunit MED12 are associated with X-linked intellectual disability tors and repressors target Mediator. The kinase module, compris- (XLID) and multiple congenital anomalies, including craniofacial, ing MED12, MED13, CDK8, and cyclin C, has been ascribed both musculoskeletal, and behavioral defects in humans with FG (or activating and repressing functions and exists in variable association Opitz-Kaveggia) and Lujan syndromes. However, the molecular with Mediator, implying that its regulatory role is restricted to a mechanism(s) underlying these phenotypes is poorly understood. subset of RNA polymerase II transcribed genes. Here we report that MED12 mutations R961W and N1007S causing Within the Mediator kinase module, MED12 is a critical trans- FG and Lujan syndromes, respectively, disrupt a Mediator-imposed ducer of regulatory information conveyed by signal-activated transcription factors linked to diverse developmental pathways, constraint on GLI3-dependent Sonic Hedgehog (SHH) signaling. We including the EGF, Notch, Wnt, and Hedgehog pathways (10–12). -
Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders
Comprehensive Skeletal Dysplasias and Disorders Panel Test code: MA3301 Is a 251 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of disorders involving the skeletal system. About Comprehensive Skeletal Dysplasias and Disorders This panel covers a broad spectrum of skeletal disorders including common and rare skeletal dysplasias (eg. achondroplasia, COL2A1 related dysplasias, diastrophic dysplasia, various types of spondylo-metaphyseal dysplasias), various ciliopathies with skeletal involvement (eg. short rib-polydactylies, asphyxiating thoracic dysplasia dysplasias and Ellis-van Creveld syndrome), various subtypes of osteogenesis imperfecta, campomelic dysplasia, slender bone dysplasias, dysplasias with multiple joint dislocations, chondrodysplasia punctata group of disorders, neonatal osteosclerotic dysplasias, osteopetrosis and related disorders, abnormal mineralization group of disorders (eg hypopohosphatasia), osteolysis group of disorders, disorders with disorganized development of skeletal components, overgrowth syndromes with skeletal involvement, craniosynostosis syndromes, dysostoses with predominant craniofacial involvement, dysostoses with predominant vertebral involvement, patellar dysostoses, brachydactylies, some disorders with limb hypoplasia-reduction defects, ectrodactyly with and without other manifestations, polydactyly-syndactyly-triphalangism group of disorders, and disorders with defects in joint formation and synostoses. Availability 4 weeks Gene Set Description